Hogan Lovells

Produced in partnership with Maegen Morrison and Danette Antao of Hogan Lovells. This Practice Note explains the cash box structure and the principles behind its use in connection with a proposed placing by a public limited company incorporated in the UK admitted to listing on the Official List of the Financial Conduct Authority and to trading on the Main Market of the London Stock Exchange. This Practice Note is equally applicable to a public limited company incorporated in the UK which is admitted to trading on AIM if a cash box structure for a placing is used.

This Practice Note provides an overview of the regulatory framework set out by Directive 93/42/EEC on medical devices (MDD), Directive 90/385/EEC on active implantable medical devices (AIMDD), which were applicable until 25 May 2021, and Directive 98/79/EC on in vitro diagnostic medical devices (IVDD), which applied until 25 May 2022, altogether the MD Directives. The MD Directives still are relevant to ‘legacy’ devices which were authorised in accordance with them for placement on the EEA market before the new regulatory regime began its application. The MD Directives will continue to be relevant as a reference for a number of years in relation to certain legacy devices for varying time periods in accordance with transitional provisions. This Practice Note explains how devices were classified, assessed (by completion of a conformity assessment) and CE marked under the MD Directives. It also considers the advertising and promotion of medical devices, counterfeit medical devices, 3D printing and mobile health.

This Practice Note is aimed primarily at brands wishing to engage with influencers (or other talent) for particular social marketing campaigns and advertising promotions in China. It covers: what constitutes ‘endorsement’ in China, disclosure requirements, types of breaches and sanctions, oversight of endorsement activities, ownership rights to sponsored content, and key provisions in China focused talent agreements.

This Practice Note deals with influencer marketing in Germany. It is aimed at social media talent (influencers) as well as at brand owners engaging in advertising. This Practice Note focuses on labelling and disclosure requirements, sanctions, and how disclosure is regulated. Subsistence of copyright in the sponsored content and key provisions in relevant agreements are also covered.

This Practice Note explains the concept of regulatory data protection (RDP), also known as ‘data exclusivity’, provides guidance on how RDP works in practice and the impact it has on the entry into the EU market of generic and biosimilar medicinal products.

This Practice Note explores the changes introduced to the regulation of medicinal products in the EU by the Falsified Medicines Directive to combat the increase in the incidence of falsified medicinal products. First, the Practice Note considers what is meant by the term ‘falsified medicinal product’, before looking at the measures introduced by the Falsified Medicines Directive: greater control of active substances, obligations for actors in the supply chain, the introduction of safety features on the packaging of medicinal products and the common logo for websites selling medicinal products. This Practice Note also provides an overview of the UK regime for falsified medicines.

Produced in partnership with Maegen Morrison and Danette Antao of Hogan Lovells. This Practice Note looks at the role and responsibilities of the key adviser appointed by a company whose securities are admitted to trading on the High Growth Segment of the Main Market as well as the application and approval process and disciplinary regime applicable to Key Advisers.

Produced in partnership with Maegen Morrison and Danette Antao of Hogan Lovells. This Practice Note highlights some key points for an overseas company to consider when proposing to offer its securities to the public in the United Kingdom, including an overview of the eligibility criteria, the applicable rules and the key continuing obligations for a company on each market.

This Practice Note looks at the selling restrictions under UK law which may apply to companies wishing to sell their equity securities to investors. In particular, this Practice Note considers the impact of the financial promotion regime and the prospectus regime and it provides some example wording of selling restrictions which are typically used in documents relating to an offering of a company's equity securities in the UK. This Practice Note was written in partnership with Maegen Morrison and Danette Antao of Hogan Lovells.

This Practice Note explains the concept of regulatory data protection (RDP), also known as ‘data exclusivity’, provides guidance on how RDP works in practice and the impact it has on the entry into the market of generic and biosimilar medicinal products.

This Practice Note looks at the regulatory information services regime through which an issuer whose transferable securities are admitted to trading on a UK regulated market must disseminate regulated information to the public.

This Practice Note explains the ‘Connected Contracts Exclusion’—Financial Services and Markets Act 2000, (Regulated Activities) Order 2001 (RAO), SI 2001/544, art 72B. Section 19 of the Financial Services and Markets Act 2000 (FSMA) contains the ‘general prohibition’, which makes undertaking a regulated activity without authorisation a criminal offence. RAO, SI 2001/544, Pt XVII sets out a number of exclusions that apply to certain regulated activity. RAO, SI 2001/544, art 72B transposed the provisions of article 1(2) of Directive 2002/92/EC, the Insurance Mediation Directive (IMD) and provides a general exclusion for activities carried on by a provider of relevant goods or services concerning connected contracts of insurance. The Directive 2016/97/EU, Insurance Distribution Directive (IDD) introduced ancillary insurance intermediaries, and is a new category. The Perimeter Guidance Manual (PERG), provides useful guidance at PERG 5.11, and is described in this Practice Note.

ARCHIVED: This Practice Note has been archived is not maintained. This Practice Note considers the impact of EU law in judicial review proceedings. It considers related grounds for judicial review and the corresponding implications of EU law on judicial review procedure (prior to the UK’s withdrawal from the EU).

Produced in partnership with Maegen Morrison and Danette Antao of Hogan Lovells. This Practice Note provides information on the former High Growth Segment of the Main Market (HGS). The HGS was closed by the London Stock Exchange on 29 July 2024 and this note has been retained for reference purposes.